Common Approaches of Cytochrome P450 (CYP) Induction Assays

References (66)

1. 1 Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays [DOI]
2. 2 Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction [DOI]
3. 3 Gene quantification using real-time quantitative PCR [DOI]
4. 4 The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
5. 5 The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010 [DOI]
6. 6 EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS [DOI]
7. 7 An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons [DOI]
8. 8 Inhibition and induction of human cytochrome P450 enzymes: current status [DOI]
9. 9 CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes [DOI]
10. 10 The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly [DOI]
11. 11 Pharmacokinetic drug-drug interaction and their implication in clinical management.
12. 12 Cell Lines: A Tool for In Vitro Drug Metabolism Studies [DOI]
13. 13 Predicting Drug–Drug Interactions: An FDA Perspective [DOI]
14. 14 CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications [DOI]
15. 15 Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective [DOI]
16. 16 HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro [DOI]
17. 17 Informatics confronts drug–drug interactions [DOI]
18. 18 Comparison of methods for evaluating drug-drug interaction [DOI]
19. 19 PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo [DOI]
20. 20 Pharmacokinetic drug interactions in liver disease: An update [DOI]
21. 21 Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical [DOI]
22. 22 Induction of drug metabolism: Species differences and toxicological relevance [DOI]
23. 23 Signaling control of the constitutive androstane receptor (CAR) [DOI]
24. 24 Post-translational and Post-transcriptional Modifications of Pregnane X Receptor (PXR) in Regulation of the Cytochrome P450 Superfamily [DOI]
25. 25 Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens [DOI]
26. 26 The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models [DOI]
27. 27 Isolation and Culture of Primary Human Hepatocytes [DOI]
28. 28 Induction of Drug Metabolising Enzymes [DOI]
29. 29 Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction [DOI]
30. 30 PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides [DOI]
31. 31 General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information [DOI]
32. 32 Induction of drug metabolizing enzymes: A survey of in vitro methodologies and interpretations used in the pharmaceutical industry—Do they comply with FDA recommendations? [DOI]
33. 33 Phosphorylation and protein–protein interactions in PXR-mediated CYP3A repression [DOI]
34. 34 CYTOCHROME P450 GENE INDUCTION IN RATS EX VIVO ASSESSED BY QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (TAQMAN) [DOI]
35. 35 Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1 [DOI]
36. 36 A Cell-Based Reporter Gene Assay for Determining Induction of CYP3A4 in a High-Volume System [DOI]
37. 37 An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR [DOI]
38. 38 Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database [DOI]
39. 39 A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism? [DOI]
40. 40 SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum [DOI]
41. 41 An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR [DOI]
42. 42 AhR activation underlies the CYP1A autoinduction by A-998679 in rats [DOI]
43. 43 Human CYPs: in vivo and clinical aspects [DOI]
44. 44 Use of a quantitative real-time reverse transcription-polymerase chain reaction method to study the induction of CYP1A, CYP2B and CYP4A forms in precision-cut rat liver slices [DOI]
45. 45 Expression of cytochrome P450s in the liver of rats administered with Socheongryong-tang, a traditional herbal formula [DOI]
46. 46 Rapid determination of rat hepatocyte mRNA induction potential using oligonucleotide probes for CYP1A1, 1A2, 3A and 4A1 [DOI]
47. 47 Development of Quantitative Reverse Transcriptase PCR Assays for Measuring Gene Expression [DOI]
48. 48 Evaluation of CYP1A1 and CYP2B1/2 m-RNA Induction in Rat Liver Slices Using the NanoString® Technology: A Novel Tool for Drug Discovery Lead Optimization [DOI]
49. 49 A novel method for real time quantitative RT-PCR. [DOI]
50. 50 Basic & clinical pharmacology & toxicology
51. 51 Cytochrome P450 Enzymes and Drug Metabolism in Humans [DOI]
52. 52 Inhibition and induction of CYP enzymes in humans: an update [DOI]
53. 53 Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis [DOI]
54. 54 Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches [DOI]
55. 55 Ex vivo gene therapy for the treatment of neurological disorders [DOI]
56. 56 Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study [DOI]
57. 57 Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia [DOI]
58. 58 A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction [DOI]
59. 59 Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1 [DOI]
60. 60 Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology [DOI]
61. 61 Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach [DOI]
62. 62 Pharmacodynamic Drug–Drug Interactions [DOI]
63. 63 Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology [DOI]
64. 64 IMPORTANCE OF SUFFICIENT TIME POINTS FOR EFFICIENT PHARMACOKINETIC (PK) COMPARTMENTAL MODELING [DOI]
65. 65 European Journal of Clinical Pharmacology [DOI]
66. 66 Prevalence of potential drug- drug interactions and associated factors among outpatients and inpatients in Ethiopian Hospitals: a systematic review and Meta-analysis of observational studies [DOI]

Cited by 1

Related research

• Linking Induction and Transrepression of PPARβ/δ with Cellular Function — shares topic coverage
• Evaluation of Anaesthetic Efficacy of Ocimum gratissimum on Clarias gariepinus Fingerlings during Transport — shares topic coverage
• Optimization of Cultural and Nutritional Parameters for the Production of Laccase by Pleurotus ostreatus ARC280 — shares topic coverage
• In vitro Apical Shoot Culture and Callus Formation of Durian (Durio zibethinus Murray) — shares topic coverage
• Expression of Blood-Brain Barrier Antigens in Non-Brain Derived Endothelial Cells Despite Lack of Astrocyte Interactions — shares topic coverage